-

12:00:51 AM

RVVTF Stock News

RVVTF - Revive Therapeutics Ltd.

01/18/22 9:02 PM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

701 subjects dosed to date Initiating enrollment activities in Turkey as part of its clinical diversification plans to support global regulatory approvals On-track to complete enrollment in Q1-2022 and FDA submission thereafter Commencing regulatory package activities for submission to

RHEA-AI

neutral

01/17/22 8:17 AM

OTC : RVVTF

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a

RHEA-AI

positive

01/06/22 4:24 PM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV)

RHEA-AI

neutral

12/29/21 4:45 PM

OTC : RVVTF

clinical trialcovid-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Screened approximately 700 subjects and expanding to Eastern Europe, including Turkey, as part of its clinical diversification plans to support global regulatory approvals No serious adverse events and safety concerns reported to date in the Phase 3 clinical trial Expected to complete enrollment in

RHEA-AI

neutral

12/03/21 9:31 AM

OTC : RVVTF

clinical trial

UPDATE -- Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529) Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2) Adding inflammatory markers along with viral load testing to current Phase 3 clinical study for COVID-19

RHEA-AI

neutral

12/03/21 8:30 AM

OTC : RVVTF

clinical trial

Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529) Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2) Adding inflammatory markers along with viral load testing to current Phase 3 clinical study for COVID-19

RHEA-AI

neutral

11/23/21 6:00 AM

OTC : RVVTF

Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has

RHEA-AI

neutral

11/16/21 6:00 AM

OTC : RVVTF

Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a research

RHEA-AI

neutral

09/21/21 9:45 AM

OTC : RVVTF

Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today that

RHEA-AI

neutral

08/17/21 5:46 PM

OTC : RVVTF

Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer

Novel discovery and research originated from Universidad Central del Caribe and St. Jude Children’s Research Hospital Medicinal mushroom compound with anticancer activities that have minimal effects on normal cells Showed superior potency against aggressive breast cancer with potential to treat

RHEA-AI

neutral

RVVTF Data:

IndustryPharmaceuticals: Major
Websitehttp://www.revivethera.com
CeoMichael Frank
Security nameRevive Therapeutics Ltd.
Issue typecs
SectorHealth Technology
Sic code2834
Tags
- Pharmaceuticals: Major
- Health Technology
AddressThe Canadian Venture Building
StateON
CityToronto
ZipM5C
CountryCA
Phone1.888.901.0036

RVVTF Description:

Revive Therapeutics Ltd. engages in the research, development, and commercialization of novel therapies and technologies for the medical cannabis and cannabinoid pharmaceuticals markets. It offers the Relicann, a proprietary hemp-based cannabidiol chewing gum for the health and wellness. Its novel cannabinoid delivery technology targets diseases and disorders such as pain, inflammation, and wound care. The company was founded by Fabio Chianelli on March 27, 2012 and is headquartered in Toronto, Canada.